Form 4: Rallybio Director Martin Mackay Acquires Options in Company

Martin Mackay, a director at Rallybio Corp, reports the acquisition of options to purchase 28,500 shares of common stock.

Summary

• On May 13, 2025, Martin Mackay, a director of Rallybio Corp, acquired options to purchase 28,500 shares of the company's common stock.
• The options were granted under the company's 2021 Equity Incentive Plan.
• The options vest on the earlier of May 13, 2026, or the date of the company's 2026 Annual Meeting of Stockholders.
• The expiration date for the options is May 13, 2035.
• Following the transaction, Mackay directly owns 28,500 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (granting of stock options) which is generally viewed as a positive sign of aligning director interests with shareholders. It's a neutral to slightly positive event.

Positives

• The granting of options to a director aligns their interests with those of the shareholders.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotechnology industry to align their interests with shareholders.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize equity-based compensation for their board members.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and company performance.

Stakeholder Impact

• The granting of options to a director can positively impact shareholders by aligning management's interests with theirs.

Key Dates

Keywords

Rallybio Corp, Martin Mackay, options, director, equity incentive plan, Form 4, RLYB